- Home
- ARVN vs AUTL Comparison
ARVN vs AUTL Comparison
Compare ARVN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- AUTL
- Stock Information
- Founded
- ARVN 2015
- AUTL 2014
- Country
- ARVN United States
- AUTL United Kingdom
- Employees
- ARVN N/A
- AUTL N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARVN Health Care
- AUTL Health Care
- Exchange
- ARVN Nasdaq
- AUTL Nasdaq
- Market Cap
- ARVN 438.1M
- AUTL 360.6M
- IPO Year
- ARVN 2018
- AUTL 2018
- Fundamental
- Price
- ARVN $8.98
- AUTL $1.47
- Analyst Decision
- ARVN Buy
- AUTL Strong Buy
- Analyst Count
- ARVN 15
- AUTL 5
- Target Price
- ARVN $31.86
- AUTL $9.32
- AVG Volume (30 Days)
- ARVN 2.8M
- AUTL 1.8M
- Earning Date
- ARVN 05-06-2025
- AUTL 05-08-2025
- Dividend Yield
- ARVN N/A
- AUTL N/A
- EPS Growth
- ARVN N/A
- AUTL N/A
- EPS
- ARVN N/A
- AUTL N/A
- Revenue
- ARVN $263,399,999.00
- AUTL $10,120,000.00
- Revenue This Year
- ARVN N/A
- AUTL $277.74
- Revenue Next Year
- ARVN N/A
- AUTL $221.89
- P/E Ratio
- ARVN N/A
- AUTL N/A
- Revenue Growth
- ARVN 235.54
- AUTL 496.00
- 52 Week Low
- ARVN $5.94
- AUTL $1.11
- 52 Week High
- ARVN $37.38
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ARVN 52.04
- AUTL 55.20
- Support Level
- ARVN $5.94
- AUTL $1.32
- Resistance Level
- ARVN $6.86
- AUTL $1.45
- Average True Range (ATR)
- ARVN 0.55
- AUTL 0.15
- MACD
- ARVN 0.58
- AUTL 0.05
- Stochastic Oscillator
- ARVN 93.47
- AUTL 86.18
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.